In December 2009, dipeptidyl peptidase-4 (DPP-4) inhibitors, "incretin enhancers"[@b1-jcm-2-2011-067],[@b2-jcm-2-2011-067] were launched into clinical use for type 2 diabetes in Japan.[@b3-jcm-2-2011-067] Shortly after its use, several cases with severe hypoglycemia were reported in Japan, in which the DPP-4 inhibitors were administered with sulfonylureas, necessitating a statement by the Japanese Diabetes Society to reduce the dose of sulfonylureas properly. Furthermore, the efficacy of DPP-4 inhibitors was much greater than expected in improvement of glycemic control in Japanese subjects with type 2 diabetes.

These findings suggest that DPP-4 inhibitors may have other action mechanisms than to stimulate insulin secretion in glucose-dependent manner. I propose here several possible mechanisms of DPP-4 inhibitors to reduce blood glucose in type 2 diabetes.

First, DPP-4 inhibitors are known to inhibit glucagon secretion.[@b1-jcm-2-2011-067]--[@b4-jcm-2-2011-067] It is plausible that a decrease in glucagon secretion is involved in the improvement of glycemic control of subjects with type 2 diabetes after DPP-4 inhibitors.

Second, DPP-4 inhibitors stimulate glucose- dependent insulinotropic peptide (GIP) secretion.[@b1-jcm-2-2011-067],[@b2-jcm-2-2011-067] Although the incretin effect of GIP is abolished in type 2 diabetes, GIP is reported to restore its action to stimulate insulin secretion, after the glycemic control has been improved both in rats and humans.[@b1-jcm-2-2011-067],[@b5-jcm-2-2011-067],[@b6-jcm-2-2011-067]

Third, it has recently been indicated that exendin-4, an "incretin mimetic", which is in fact a GLP-1 paralog,[@b7-jcm-2-2011-067] causes an elevation of impaired ATP production by high glucose in islets of diabetic rats.[@b8-jcm-2-2011-067] Therefore, it is plausible that DPP-4 inhibitors may recover the response to sulfonylureas by restoring pancreatic ATP levels.

Fourth, it has very recently been reported, in an abstract form, that sitagliptin, one of the DPP-4 inhibitors, may stimulate glucagon-like peptide 1 (GLP-1) secretion directly from the intestine.[@b9-jcm-2-2011-067] Further studies are required to evaluate whether this effect is due to DPP-4 inhibition, and it has clinical effect in humans.

Fifth and finally, DPP-4 has been reported to act as an adipokine, which may be positively linked to insulin resistance.[@b10-jcm-2-2011-067] Although the physiological significance of these findings remains to be elucidated, it is possible that DPP-4 inhibitors may inhibit the action of DPP-4 as an adipokine, resulting in an improvement of insulin resistance.

Further studies are justified to investigate whether the possible mechanisms of DPP-4 inhibitors presented here may have clinical significance in the treatment of type 2 diabetes with DPP-4 inhibitors.
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